- Home
- Publications
- Publication Search
- Publication Details
Title
Overcoming Oncogenic Mediated Tumor Immunity in Prostate Cancer
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 18, Issue 7, Pages 1542
Publisher
MDPI AG
Online
2017-07-18
DOI
10.3390/ijms18071542
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer
- (2017) Tomasz M. Beer et al. JOURNAL OF CLINICAL ONCOLOGY
- Effective combinatorial immunotherapy for castration-resistant prostate cancer
- (2017) Xin Lu et al. NATURE
- Integrating liquid biopsies into the management of cancer
- (2017) Giulia Siravegna et al. Nature Reviews Clinical Oncology
- Extracellular vesicles for liquid biopsy in prostate cancer: where are we and where are we headed?
- (2017) V R Minciacchi et al. PROSTATE CANCER AND PROSTATIC DISEASES
- Aberrant corticosteroid metabolism in tumor cells enables GR takeover in enzalutamide resistant prostate cancer
- (2017) Jianneng Li et al. eLife
- Prostate Cancer, Version 2.2014
- (2017) James L. Mohler et al. Journal of the National Comprehensive Cancer Network
- Clinical variability and molecular heterogeneity in prostate cancer
- (2016) ChristopherE Barbieri et al. ASIAN JOURNAL OF ANDROLOGY
- Cancer statistics, 2016
- (2016) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
- (2016) Jianjun Gao et al. CELL
- Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial
- (2016) Emmanuel S. Antonarakis et al. CLINICAL CANCER RESEARCH
- MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade
- (2016) Peter J.R. Ebert et al. IMMUNITY
- A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy
- (2016) Rana R. McKay et al. JOURNAL OF CLINICAL ONCOLOGY
- Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer
- (2016) Himisha Beltran et al. NATURE MEDICINE
- T-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
- (2016) Eric Tran et al. NEW ENGLAND JOURNAL OF MEDICINE
- Androgen receptor antagonists compromise T cell response against prostate cancer leading to early tumor relapse
- (2016) Yang Pu et al. Science Translational Medicine
- Non‑invasive prostate cancer detection by measuring miRNA variants (isomiRs) in urine extracellular vesicles
- (2016) Danijela Koppers-Lalic et al. Oncotarget
- Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone
- (2016) Cristian Lolli et al. Frontiers in Pharmacology
- Modulation of Inflammatory Responses by Wnt/β-Catenin Signaling in Dendritic Cells: A Novel Immunotherapy Target for Autoimmunity and Cancer
- (2016) Amol Suryawanshi et al. Frontiers in Immunology
- Does Radiotherapy for the Primary Tumor Benefit Prostate Cancer Patients with Distant Metastasis at Initial Diagnosis?
- (2016) Yeona Cho et al. PLoS One
- Prostate-specific extracellular vesicles as a novel biomarker in human prostate cancer
- (2016) Yong Hyun Park et al. Scientific Reports
- Dexamethasone enhances programmed cell death 1 (PD-1) expression during T cell activation: an insight into the optimum application of glucocorticoids in anti-cancer therapy
- (2015) Kailin Xing et al. BMC IMMUNOLOGY
- PTEN loss in circulating tumour cells correlates with PTEN loss in fresh tumour tissue from castration-resistant prostate cancer patients
- (2015) Elizabeth A Punnoose et al. BRITISH JOURNAL OF CANCER
- CSF1 Receptor Targeting in Prostate Cancer Reverses Macrophage-Mediated Resistance to Androgen Blockade Therapy
- (2015) J. Escamilla et al. CANCER RESEARCH
- Classifying Cancers Based on T-cell Infiltration and PD-L1
- (2015) Michele W.L. Teng et al. CANCER RESEARCH
- Integrative Clinical Genomics of Advanced Prostate Cancer
- (2015) Dan Robinson et al. CELL
- The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer
- (2015) H. Gevensleben et al. CLINICAL CANCER RESEARCH
- Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
- (2015) A. A. Azad et al. CLINICAL CANCER RESEARCH
- RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
- (2015) S. Loi et al. CLINICAL CANCER RESEARCH
- Exosomal miR-1290 and miR-375 as Prognostic Markers in Castration-resistant Prostate Cancer
- (2015) Xiaoyi Huang et al. EUROPEAN UROLOGY
- PDL1 Regulation by p53 via miR-34
- (2015) Maria Angelica Cortez et al. JNCI-Journal of the National Cancer Institute
- The evolutionary history of lethal metastatic prostate cancer
- (2015) Gunes Gundem et al. NATURE
- Intrapatient heterogeneity in prostate cancer
- (2015) Himisha Beltran et al. Nature Reviews Urology
- The Genetic Evolution of Melanoma from Precursor Lesions
- (2015) A. Hunter Shain et al. NEW ENGLAND JOURNAL OF MEDICINE
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- The oncogene ERG: a key factor in prostate cancer
- (2015) P Adamo et al. ONCOGENE
- Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance
- (2015) A M Martin et al. PROSTATE CANCER AND PROSTATIC DISEASES
- APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
- (2015) N Mohell et al. Cell Death & Disease
- Alternatively activated macrophages are associated with metastasis and poor prognosis in prostate adenocarcinoma
- (2015) WENXUE HU et al. Oncology Letters
- Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer
- (2015) Matthew K.H. Hong et al. Nature Communications
- Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy
- (2015) W. Peng et al. Cancer Discovery
- Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression
- (2015) G. Wang et al. Cancer Discovery
- Secreted Factors from Colorectal and Prostate Cancer Cells Skew the Immune Response in Opposite Directions
- (2015) Marie Lundholm et al. Scientific Reports
- SPOP mutation leads to genomic instability in prostate cancer
- (2015) Gunther Boysen et al. eLife
- PDL1 Regulation by p53 via miR-34
- (2015) Maria Angelica Cortez et al. JNCI-Journal of the National Cancer Institute
- CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
- (2015) T. Higuchi et al. Cancer Immunology Research
- New perspective on targeting the tumor suppressor p53 pathway in the tumor microenvironment to enhance the efficacy of immunotherapy
- (2015) Gang Guo et al. Journal for ImmunoTherapy of Cancer
- Inhibition of Immune Checkpoints and Vascular Endothelial Growth Factor as Combination Therapy for Metastatic Melanoma: An Overview of Rationale, Preclinical Evidence, and Initial Clinical Data
- (2015) Patrick A. Ott et al. Frontiers in Oncology
- Immune Infiltration and Prostate Cancer
- (2015) Amy Strasner et al. Frontiers in Oncology
- PD-L1 is highly expressed in Enzalutamide resistant prostate cancer
- (2015) Jennifer L. Bishop et al. Oncotarget
- Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy
- (2014) Jens G. Lohr et al. CANCER CELL
- Chronic Inflammation in Benign Prostate Tissue Is Associated with High-Grade Prostate Cancer in the Placebo Arm of the Prostate Cancer Prevention Trial
- (2014) B. Gurel et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Programmed Cell Death 1 (PD-1) and Its Ligand (PD-L1) in Common Cancers and Their Correlation with Molecular Cancer Type
- (2014) Z. Gatalica et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- NF- B Gene Signature Predicts Prostate Cancer Progression
- (2014) R. Jin et al. CANCER RESEARCH
- CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling
- (2014) Randall J. Platt et al. CELL
- Aspirin, NSAIDs, and Risk of Prostate Cancer: Results from the REDUCE Study
- (2014) A. C. Vidal et al. CLINICAL CANCER RESEARCH
- Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
- (2014) M. Atefi et al. CLINICAL CANCER RESEARCH
- Androgen Receptor as a Driver of Therapeutic Resistance in Advanced Prostate Cancer
- (2014) Barbara Kahn et al. International Journal of Biological Sciences
- Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
- (2014) Suzanne L. Topalian et al. JOURNAL OF CLINICAL ONCOLOGY
- Activated Lymphocyte Recruitment Into the Tumor Microenvironment Following Preoperative Sipuleucel-T for Localized Prostate Cancer
- (2014) Lawrence Fong et al. JNCI-Journal of the National Cancer Institute
- Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial
- (2014) Eugene D Kwon et al. LANCET ONCOLOGY
- Pten Null Prostate Epithelium Promotes Localized Myeloid-Derived Suppressor Cell Expansion and Immune Suppression during Tumor Initiation and Progression
- (2014) A. J. Garcia et al. MOLECULAR AND CELLULAR BIOLOGY
- Emerging mechanisms of enzalutamide resistance in prostate cancer
- (2014) Frank Claessens et al. Nature Reviews Urology
- Analysis of Tim-3 as a therapeutic target in prostate cancer
- (2014) Yong-Rui Piao et al. TUMOR BIOLOGY
- p38 MAPK-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T-cell-mediated immunosuppression
- (2014) Yong Lu et al. Nature Communications
- NF-κB Functions in Tumor Initiation by Suppressing the Surveillance of Both Innate and Adaptive Immune Cells
- (2014) David J. Wang et al. Cell Reports
- Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade
- (2014) Z. A. Cooper et al. Cancer Immunology Research
- Selective Depletion of Regulatory T Cell Subsets by Docetaxel Treatment in Patients with Nonsmall Cell Lung Cancer
- (2014) Jie-Yao Li et al. Journal of Immunology Research
- Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
- (2013) S. F. Slovin et al. ANNALS OF ONCOLOGY
- ERG Is a Critical Regulator of Wnt/LEF1 Signaling in Prostate Cancer
- (2013) L. Wu et al. CANCER RESEARCH
- Trp53 Inactivation in the Tumor Microenvironment Promotes Tumor Progression by Expanding the Immunosuppressive Lymphoid-like Stromal Network
- (2013) G. Guo et al. CANCER RESEARCH
- Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade
- (2013) Vivek K. Arora et al. CELL
- The complexity of NF-κB signaling in inflammation and cancer
- (2013) Bastian Hoesel et al. Molecular Cancer
- PTEN functions as a melanoma tumor suppressor by promoting host immune response
- (2013) Y Dong et al. ONCOGENE
- Lower Baseline Prostate-specific Antigen Is Associated With a Greater Overall Survival Benefit From Sipuleucel-T in the Immunotherapy for Prostate Adenocarcinoma Treatment (IMPACT) Trial
- (2013) Paul F. Schellhammer et al. UROLOGY
- Anti-androgen receptor ASC-J9 versus anti-androgens MDV3100 (Enzalutamide) or Casodex (Bicalutamide) leads to opposite effects on prostate cancer metastasis via differential modulation of macrophage infiltration and STAT3-CCL2 signaling
- (2013) T-H Lin et al. Cell Death & Disease
- Immune Impact Induced by PROSTVAC (PSA-TRICOM), a Therapeutic Vaccine for Prostate Cancer
- (2013) J. L. Gulley et al. Cancer Immunology Research
- Androgen Receptor Influences on Body Defense System via Modulation of Innate and Adaptive Immune Systems
- (2012) Jiann-Jyh Lai et al. AMERICAN JOURNAL OF PATHOLOGY
- Increased CD8+ T-cell Function following Castration and Immunization Is Countered by Parallel Expansion of Regulatory T Cells
- (2012) S. Tang et al. CANCER RESEARCH
- Pten Loss and RAS/MAPK Activation Cooperate to Promote EMT and Metastasis Initiated from Prostate Cancer Stem/Progenitor Cells
- (2012) D. J. Mulholland et al. CANCER RESEARCH
- Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma
- (2012) J. S. Khalili et al. CLINICAL CANCER RESEARCH
- The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
- (2012) X. Jiang et al. CLINICAL CANCER RESEARCH
- High tissue density of FOXP3+ T cells is associated with clinical outcome in prostate cancer
- (2012) Anna Flammiger et al. EUROPEAN JOURNAL OF CANCER
- Targeting p53 in Vivo: A First-in-Human Study With p53-Targeting Compound APR-246 in Refractory Hematologic Malignancies and Prostate Cancer
- (2012) Sören Lehmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
- (2012) Axel Hauschild et al. LANCET
- Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation
- (2012) Jennifer Landsberg et al. NATURE
- Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer
- (2012) Christopher E Barbieri et al. NATURE GENETICS
- Immunologic Correlates of the Abscopal Effect in a Patient with Melanoma
- (2012) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regulatory T cells in the bone marrow microenvironment in patients with prostate cancer
- (2012) Ende Zhao et al. OncoImmunology
- Upregulation of MAPK pathway is associated with survival in castrate-resistant prostate cancer
- (2011) R Mukherjee et al. BRITISH JOURNAL OF CANCER
- PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine
- (2011) M. A. Cheever et al. CLINICAL CANCER RESEARCH
- Activation of mitogen activated protein kinase-Erk kinase (MEK) increases T cell immunoglobulin mucin domain-3 (TIM-3) transcription in human T lymphocytes and a human mast cell line
- (2011) Soo-Jin Yoon et al. MOLECULAR IMMUNOLOGY
- Distribution of Foxp3-, CD4- and CD8-positive lymphocytic cells in benign and malignant prostate tissue
- (2010) ALEXANDER VALDMAN et al. APMIS
- Infiltration of tumour-associated macrophages in prostate biopsy specimens is predictive of disease progression after hormonal therapy for prostate cancer
- (2010) Norio Nonomura et al. BJU INTERNATIONAL
- Total Therapy 3 for multiple myeloma: prognostic implications of cumulative dosing and premature discontinuation of VTD maintenance components, bortezomib, thalidomide, and dexamethasone, relevant to all phases of therapy
- (2010) F. van Rhee et al. BLOOD
- Integrative Genomic Profiling of Human Prostate Cancer
- (2010) Barry S. Taylor et al. CANCER CELL
- A Novel Chemoimmunomodulating Property of Docetaxel: Suppression of Myeloid-Derived Suppressor Cells in Tumor Bearers
- (2010) K. N. Kodumudi et al. CLINICAL CANCER RESEARCH
- Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. JOURNAL OF CLINICAL ONCOLOGY
- The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights
- (2010) Agnes E. Coutinho et al. MOLECULAR AND CELLULAR ENDOCRINOLOGY
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
- (2010) Philip W. Kantoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- TGF-β and immune cells: an important regulatory axis in the tumor microenvironment and progression
- (2010) Li Yang et al. TRENDS IN IMMUNOLOGY
- Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer
- (2009) Celestia S. Higano et al. CANCER
- Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
- (2009) James L. Gulley et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer
- (2009) Ravi A Madan et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients
- (2009) Philippe O. Gannon et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Combination of Docetaxel and Recombinant Vaccine Enhances T-Cell Responses and Antitumor Activity: Effects of Docetaxel on Immune Enhancement
- (2008) C. T. Garnett et al. CLINICAL CANCER RESEARCH
- Phenotypic Analysis of Prostate-Infiltrating Lymphocytes Reveals TH17 and Treg Skewing
- (2008) K. S. Sfanos et al. CLINICAL CANCER RESEARCH
- Targeting the androgen receptor pathway in prostate cancer
- (2008) Yu Chen et al. CURRENT OPINION IN PHARMACOLOGY
- Radiotherapy augments the immune response to prostate cancer in a time-dependent manner
- (2008) Timothy J. Harris et al. PROSTATE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started